Donepezil, 99%

Name: Donepezil, 99% | 120014-06-4
Brand: J&K Chemical
SKU: JK172570_25_MG
Price: 287.0 USD
Availability: InStock

Cat. No JK172570_25_MG

Vendor: J&K Chemical

Product Information

Product Name

Donepezil, 99%

Brand Name

J&K

Product Number

172570

CAS

120014-06-4

Molecular Formula

C24H29NO3

Molecular Weight

379.50

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

3152

IUPAC Name

2-(1-benzylpiperidin-4-yl)methyl-5,6-dimethoxy-2,3-dihydroinden-1-one

InChI Key

ADEBPBSSDYVVLD-UHFFFAOYSA-N

SMILES

COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC

Safety Information

GHS Symbols

Signal Word

Warning

Hazard Statement

H315

H319

H335

Precautionary Statement

P280

P321

P261

P271

P319

P405

P501

P302+P352

P332+P317

P362+P364

P264+P265

P305+P351+P338

P337+P317

P304+P340

P403+P233

References Data Source From Pubchem

Correction: Tailoring treatments: pharmacogenomics in the management of neurodegenerative diseases

Publication Name: Acta Neurologica Belgica

Publication Date: 2026-06-15

DOI: 10.1007/s13760-025-02919-4|10.1007/s13760-026-03095-9

Exploring the Gut-Brain Connection: Are Probiotics the Next Frontier in Alzheimer’s Disease Treatment?

Publication Name: Probiotics and Antimicrobial Proteins

Publication Date: 2026-03-04

DOI: 10.1007/s12602-026-10927-w

Current advances in 7-hydroxycoumarin derivatives as potential therapeutic agents for Alzheimer’s disease

Publication Name: Molecular Diversity

Publication Date: 2026-03-04

DOI: 10.1007/s11030-026-11503-8

Functional and structural retinal alterations in Alzheimer’s disease: insights from photopic negative response (PhNR) and OCT-based analysis

Publication Name: Documenta ophthalmologica. Advances in ophthalmology

Publication Date: 2026-03-04

DOI: 10.1007/s10633-026-10089-8

Breaking the Barrier of Brain Disease Therapeutics: Advocating Targeted Drug Delivery for Improved Neuro-Resident Interventions

Publication Name: AAPS PharmSciTech

Publication Date: 2026-03-04

DOI: 10.1208/s12249-026-03386-7

Donepezil, 99%

Product Information

General Information

Safety Information

References Data Source From Pubchem

Correction: Tailoring treatments: pharmacogenomics in the management of neurodegenerative diseases

Exploring the Gut-Brain Connection: Are Probiotics the Next Frontier in Alzheimer’s Disease Treatment?

Current advances in 7-hydroxycoumarin derivatives as potential therapeutic agents for Alzheimer’s disease

Functional and structural retinal alterations in Alzheimer’s disease: insights from photopic negative response (PhNR) and OCT-based analysis

Breaking the Barrier of Brain Disease Therapeutics: Advocating Targeted Drug Delivery for Improved Neuro-Resident Interventions

Donepezil, 99%

About Us

Popular Searches

Contact

#title#

Features
Availability:
Price
Options
Actions

Donepezil, 99%

Product Information

General Information

Safety Information

References Data Source From Pubchem

Correction: Tailoring treatments: pharmacogenomics in the management of neurodegenerative diseases

Exploring the Gut-Brain Connection: Are Probiotics the Next Frontier in Alzheimer’s Disease Treatment?

Current advances in 7-hydroxycoumarin derivatives as potential therapeutic agents for Alzheimer’s disease

Functional and structural retinal alterations in Alzheimer’s disease: insights from photopic negative response (PhNR) and OCT-based analysis

Breaking the Barrier of Brain Disease Therapeutics: Advocating Targeted Drug Delivery for Improved Neuro-Resident Interventions

Donepezil, 99%

Related Product

#title#

Login

Register